Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase

Executive Summary

The agency requested a funding increase in part to implement 2018 legislation intended to combat the opioid crisis, but also to support many initiatives in last year's budget request.

You may also be interested in...



FDA Review Modernization Fully Funded

After receiving $25.1m in FY 2019, Congress gave another $1.9m in FY 2020, which appropriators said combined reaches the $27m requested for the FY 2020 budget.

Generics Modernization Effort At US FDA Receives Full Funding Over Two Years

After receiving $25.1m in FY 2019, Congress gave another $1.9m in FY 2020, which appropriators said combined reaches the $27m requested for the FY 2020 budget.

US FDA Gets Another Appropriations Increase In FY 2020 House Bill

Overall percentage increase is not as high as the FY 2019 spending bill, but stakeholders are happy with the proposed boost in budget authority.

Related Content

Topics

UsernamePublicRestriction

Register

PS124946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel